Skip to main content
Top
Gepubliceerd in: Bijblijven 2/2018

20-03-2018

Behandeling met biologicals bij systeemziekten en ILD

Auteurs: Dr. Marcel Veltkamp, Drs. Milou C. Schimmelpennink

Gepubliceerd in: Bijblijven | Uitgave 2/2018

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Sommige patiënten met therapieresistente chronische sarcoïdose komen in aanmerking voor een derdelijns behandeling met TNF-alfaremmers. Middelen zoals infliximab en adalimumab zijn beide effectief gebleken in de behandeling van patiënten met chronische therapieresistente sarcoïdose.
Bij collageen-vasculaire ziekten geassocieerd met ernstige therapieresistente interstitiële longafwijkingen wordt door de longarts met name de biological rituximab voorgeschreven.
Door onderdrukking van het immuunsysteem bij het gebruik van TNF-alfaremmers zijn patiënten gevoeliger voor infecties of voor reactivatie van latente infecties (bijvoorbeeld tuberculose) en kunnen infecties atypisch en/of acuut verlopen. Bij tekenen van infectie is het wenselijk dat de huisarts contact opneemt met de behandelend longarts. Tevens kunnen patiënten die TNF-alfaremmers gebruiken antilichamen vormen. Dit vermindert de werking van het medicijn en kan allergische reacties veroorzaken.
Het is de verwachting dat het gebruik van biologicals in de toekomst alleen maar zal toenemen, zodat ook de huisarts in zijn of haar praktijk hiermee vaker geconfronteerd zal worden.
Literatuur
1.
go back to reference Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2011;305(4):391–9.CrossRefPubMed Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2011;305(4):391–9.CrossRefPubMed
2.
go back to reference Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J. 1999;14(4):735–7.CrossRefPubMed Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J. 1999;14(4):735–7.CrossRefPubMed
3.
go back to reference Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis. 1973;107(4):609–14.CrossRefPubMed Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis. 1973;107(4):609–14.CrossRefPubMed
4.
go back to reference James DG, Carstairs LS, Trowell J, Sharma OP. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet. 1967;2(7515):526–8.CrossRefPubMed James DG, Carstairs LS, Trowell J, Sharma OP. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet. 1967;2(7515):526–8.CrossRefPubMed
5.
go back to reference Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O, Finnish Pulmonary Sarcoidosis Study Group. Early treatment of stage II sarcoidosis improves 5‑year pulmonary function. Chest. 2002;121(1):24–31.CrossRefPubMed Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O, Finnish Pulmonary Sarcoidosis Study Group. Early treatment of stage II sarcoidosis improves 5‑year pulmonary function. Chest. 2002;121(1):24–31.CrossRefPubMed
6.
go back to reference Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis. 1990;142(6 Pt 1):1268–71.CrossRefPubMed Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis. 1990;142(6 Pt 1):1268–71.CrossRefPubMed
7.
go back to reference Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17(1):60–6.PubMed Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17(1):60–6.PubMed
8.
go back to reference Vorselaars AD, Wuyts WA, Vorselaars VM, Zanen P, Deneer VH, Veltkamp M, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013;144(3):805–12.CrossRefPubMed Vorselaars AD, Wuyts WA, Vorselaars VM, Zanen P, Deneer VH, Veltkamp M, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013;144(3):805–12.CrossRefPubMed
9.
go back to reference Dai H, Guzman J, Chen B, Costabel U. Production of soluble tumor necrosis factor receptors and tumor necrosis factor-alpha by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis. Chest. 2005;127(1):251–6.CrossRefPubMed Dai H, Guzman J, Chen B, Costabel U. Production of soluble tumor necrosis factor receptors and tumor necrosis factor-alpha by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis. Chest. 2005;127(1):251–6.CrossRefPubMed
10.
go back to reference Matej R, Smetakova M, Vasakova M, Novakova J, Sterclova M, Kukal J, et al. PAR-2, IL-4R, TGF-beta and TNF-alpha in bronchoalveolar lavage distinguishes extrinsic allergic alveolitis from sarcoidosis. Exp Ther Med. 2014;8(2):533–8.CrossRefPubMedPubMedCentral Matej R, Smetakova M, Vasakova M, Novakova J, Sterclova M, Kukal J, et al. PAR-2, IL-4R, TGF-beta and TNF-alpha in bronchoalveolar lavage distinguishes extrinsic allergic alveolitis from sarcoidosis. Exp Ther Med. 2014;8(2):533–8.CrossRefPubMedPubMedCentral
11.
go back to reference Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159(2):508–11.CrossRefPubMed Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159(2):508–11.CrossRefPubMed
12.
go back to reference Vorselaars AD, Crommelin HA, Deneer VH, Meek B, Claessen AM, Keijsers RG, et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J. 2015;46(1):175–85.CrossRefPubMed Vorselaars AD, Crommelin HA, Deneer VH, Meek B, Claessen AM, Keijsers RG, et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J. 2015;46(1):175–85.CrossRefPubMed
13.
go back to reference Murdaca G, Spano F, Contatore M, Guastalla A, Penza E, Magnani O, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15(1):43–52.CrossRefPubMed Murdaca G, Spano F, Contatore M, Guastalla A, Penza E, Magnani O, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15(1):43–52.CrossRefPubMed
14.
go back to reference Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, Bois R du, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802.CrossRefPubMed Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, Bois R du, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802.CrossRefPubMed
15.
go back to reference Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis. 2004;63(3):318–20.CrossRefPubMedPubMedCentral Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis. 2004;63(3):318–20.CrossRefPubMedPubMedCentral
16.
go back to reference Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med. 2006;100(11):2053–9.CrossRefPubMed Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med. 2006;100(11):2053–9.CrossRefPubMed
17.
go back to reference Cohen Aubart F, Bouvry D, Galanaud D, Dehais C, Mathey G, Psimaras D, et al. Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol. 2017;264(5):891–7.CrossRefPubMed Cohen Aubart F, Bouvry D, Galanaud D, Dehais C, Mathey G, Psimaras D, et al. Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol. 2017;264(5):891–7.CrossRefPubMed
18.
go back to reference Orum M, Hilberg O, Krag S, Bendstrup E. Beneficial effect of infliximab on refractory sarcoidosis. Dan Med J. 2012;59(12):A4535.PubMed Orum M, Hilberg O, Krag S, Bendstrup E. Beneficial effect of infliximab on refractory sarcoidosis. Dan Med J. 2012;59(12):A4535.PubMed
19.
go back to reference Croft AP, Situnayake D, Khair O, Giovanni G, Carruthers D, Sivaguru A, et al. Refractory multisystem sarcoidosis responding to infliximab therapy. Clin Rheumatol. 2012;31(6):1013–8.CrossRefPubMed Croft AP, Situnayake D, Khair O, Giovanni G, Carruthers D, Sivaguru A, et al. Refractory multisystem sarcoidosis responding to infliximab therapy. Clin Rheumatol. 2012;31(6):1013–8.CrossRefPubMed
20.
go back to reference Santos E, Shaunak S, Renowden S, Scolding NJ. Treatment of refractory neurosarcoidosis with Infliximab. J Neurol Neurosurg Psychiatr. 2010;81(3):241–6.CrossRef Santos E, Shaunak S, Renowden S, Scolding NJ. Treatment of refractory neurosarcoidosis with Infliximab. J Neurol Neurosurg Psychiatr. 2010;81(3):241–6.CrossRef
21.
go back to reference Riancho-Zarrabeitia L, Calvo-Rio V, Blanco R, Mesquida M, Adan AM, Herreras JM, et al. Anti-TNF-alpha therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Semin Arthritis Rheum. 2015;45(3):361–8.CrossRefPubMed Riancho-Zarrabeitia L, Calvo-Rio V, Blanco R, Mesquida M, Adan AM, Herreras JM, et al. Anti-TNF-alpha therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Semin Arthritis Rheum. 2015;45(3):361–8.CrossRefPubMed
22.
go back to reference Vorselaars AD, Verwoerd A, Moorsel CH van, Keijsers RG, Rijkers GT, Grutters JC. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J. 2014;43(2):602–9.CrossRefPubMed Vorselaars AD, Verwoerd A, Moorsel CH van, Keijsers RG, Rijkers GT, Grutters JC. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J. 2014;43(2):602–9.CrossRefPubMed
23.
go back to reference Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology. 2009;14(4):522–8.CrossRefPubMed Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology. 2009;14(4):522–8.CrossRefPubMed
24.
go back to reference Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765–73.CrossRefPubMed Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765–73.CrossRefPubMed
25.
go back to reference Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250(5):713–20.CrossRefPubMed Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250(5):713–20.CrossRefPubMed
26.
go back to reference Crommelin HA, Burg LM van der, Vorselaars AD, Drent M, Moorsel CH van, Rijkers GT, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med. 2016;115:72–7.CrossRefPubMed Crommelin HA, Burg LM van der, Vorselaars AD, Drent M, Moorsel CH van, Rijkers GT, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med. 2016;115:72–7.CrossRefPubMed
27.
go back to reference Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44(5):1296–307.CrossRefPubMed Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44(5):1296–307.CrossRefPubMed
28.
go back to reference Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest. 2005;128(2):1062–7.CrossRefPubMed Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest. 2005;128(2):1062–7.CrossRefPubMed
29.
go back to reference Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177–85.CrossRefPubMed Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177–85.CrossRefPubMed
30.
go back to reference Vieira MA, Saraiva MI, Silva LK, Fraga RC, Kakizaki P, Valente NY. Development of exclusively cutaneous sarcoidosis in patient with rheumatoid arthritis during treatment with etanercept. Rev Assoc Med Bras. 1992;62(8):718–20.CrossRef Vieira MA, Saraiva MI, Silva LK, Fraga RC, Kakizaki P, Valente NY. Development of exclusively cutaneous sarcoidosis in patient with rheumatoid arthritis during treatment with etanercept. Rev Assoc Med Bras. 1992;62(8):718–20.CrossRef
31.
go back to reference Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol. 2007;26(11):1969–71.CrossRefPubMed Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol. 2007;26(11):1969–71.CrossRefPubMed
32.
go back to reference Zidi I, Mestiri S, Bartegi A, Amor NB. TNF-alpha and its inhibitors in cancer. Med Oncol. 2010;27(2):185–98.CrossRefPubMed Zidi I, Mestiri S, Bartegi A, Amor NB. TNF-alpha and its inhibitors in cancer. Med Oncol. 2010;27(2):185–98.CrossRefPubMed
33.
go back to reference Callejas-Rubio JL, Lopez-Perez L, Ortego-Centeno N. Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis. Ther Clin Risk Manag. 2008;4(6):1305–13.CrossRefPubMedPubMedCentral Callejas-Rubio JL, Lopez-Perez L, Ortego-Centeno N. Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis. Ther Clin Risk Manag. 2008;4(6):1305–13.CrossRefPubMedPubMedCentral
34.
go back to reference Gilca GE, Diaconescu S, Balan GG, Timofte O, Stefanescu G. Sarcoidosis associated with infliximab therapy in ulcerative colitis: a case report. Medicine (Baltimore). 2017;96(10):e6156.CrossRef Gilca GE, Diaconescu S, Balan GG, Timofte O, Stefanescu G. Sarcoidosis associated with infliximab therapy in ulcerative colitis: a case report. Medicine (Baltimore). 2017;96(10):e6156.CrossRef
35.
go back to reference Daien CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48(8):883–6.CrossRef Daien CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48(8):883–6.CrossRef
36.
go back to reference Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol. 2008;26(3):471–5.PubMed Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol. 2008;26(3):471–5.PubMed
37.
go back to reference Baha A, Hanazay C, Kokturk N, Turktas H. A case of Sarcoidosis associated with anti-tumor necrosis factor treatment. J Investig Med High Impact Case Rep. 2015;3(1):2324709615571366.PubMedPubMedCentral Baha A, Hanazay C, Kokturk N, Turktas H. A case of Sarcoidosis associated with anti-tumor necrosis factor treatment. J Investig Med High Impact Case Rep. 2015;3(1):2324709615571366.PubMedPubMedCentral
38.
go back to reference Amber KT, Bloom R, Mrowietz U, Hertl M. TNF-alpha: a treatment target or cause of sarcoidosis? J Eur Acad Dermatol Venereol. 2015;29(11):2104–11.CrossRefPubMed Amber KT, Bloom R, Mrowietz U, Hertl M. TNF-alpha: a treatment target or cause of sarcoidosis? J Eur Acad Dermatol Venereol. 2015;29(11):2104–11.CrossRefPubMed
39.
go back to reference Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368–76.CrossRefPubMed Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368–76.CrossRefPubMed
40.
go back to reference Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101(8):1834–40.CrossRefPubMed Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101(8):1834–40.CrossRefPubMed
41.
go back to reference Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61(3):305–12.CrossRefPubMed Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61(3):305–12.CrossRefPubMed
42.
go back to reference Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737–44.CrossRefPubMed Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737–44.CrossRefPubMed
43.
go back to reference Yonekura CL, Oliveira RDR, Titton DC, Ranza R, Ranzolin A, Hayata AL, et al. Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoracao de Terapias Biologicas – BiobadaBrasil). Rev Bras Reumatol Engl Ed. 2017;57(Suppl 2):477–83.CrossRefPubMed Yonekura CL, Oliveira RDR, Titton DC, Ranza R, Ranzolin A, Hayata AL, et al. Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoracao de Terapias Biologicas – BiobadaBrasil). Rev Bras Reumatol Engl Ed. 2017;57(Suppl 2):477–83.CrossRefPubMed
44.
go back to reference Dapavo P, Vujic I, Fierro MT, Quaglino P, Sanlorenzo M. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(4):736–9.CrossRefPubMed Dapavo P, Vujic I, Fierro MT, Quaglino P, Sanlorenzo M. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(4):736–9.CrossRefPubMed
45.
go back to reference Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–12.CrossRefPubMedPubMedCentral Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–12.CrossRefPubMedPubMedCentral
46.
go back to reference Razanskaite V, Bettey M, Downey L, Wright J, Callaghan J, Rush M, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11(6):690–6.PubMed Razanskaite V, Bettey M, Downey L, Wright J, Callaghan J, Rush M, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11(6):690–6.PubMed
47.
go back to reference Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–20.CrossRefPubMedPubMedCentral Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–20.CrossRefPubMedPubMedCentral
48.
go back to reference Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–16.CrossRefPubMed Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–16.CrossRefPubMed
50.
go back to reference Wells AU, Denton CP. Interstitial lung disease in connective tissue disease – mechanisms and management. Nat Rev Rheumatol. 2014;10(12):728–39.CrossRefPubMed Wells AU, Denton CP. Interstitial lung disease in connective tissue disease – mechanisms and management. Nat Rev Rheumatol. 2014;10(12):728–39.CrossRefPubMed
51.
go back to reference Voortman M, Borg EJ ter, Kruizen AA, Radstake TR, Zanen P, Jong PA de, Heuvel D van den, Grutters JC. Interstitial lung disease in patients with Sjogren’s syndrome: correlation of radiology, pathology, and clinical phenotype. Poster session presented at the American Thoracic Society; Washington D.C. 2017. Voortman M, Borg EJ ter, Kruizen AA, Radstake TR, Zanen P, Jong PA de, Heuvel D van den, Grutters JC. Interstitial lung disease in patients with Sjogren’s syndrome: correlation of radiology, pathology, and clinical phenotype. Poster session presented at the American Thoracic Society; Washington D.C. 2017.
52.
go back to reference Khanna D, Denton CP, Lin CJ, Laar JM van, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faScinate). Ann Rheum Dis. 2018;77(2):212–20.CrossRefPubMed Khanna D, Denton CP, Lin CJ, Laar JM van, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faScinate). Ann Rheum Dis. 2018;77(2):212–20.CrossRefPubMed
54.
go back to reference Smith V, Piette Y, Praet JT van, Decuman S, Deschepper E, Elewaut D, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52–7.CrossRefPubMed Smith V, Piette Y, Praet JT van, Decuman S, Deschepper E, Elewaut D, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52–7.CrossRefPubMed
55.
go back to reference Jordan S, Distler JH, Maurer B, Huscher D, Laar JM van, Allanore Y, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188–94.CrossRefPubMed Jordan S, Distler JH, Maurer B, Huscher D, Laar JM van, Allanore Y, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188–94.CrossRefPubMed
56.
go back to reference Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford). 2009;48(8):968–71.CrossRef Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford). 2009;48(8):968–71.CrossRef
57.
go back to reference Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J. 2012;40(3):641–8.CrossRefPubMed Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J. 2012;40(3):641–8.CrossRefPubMed
58.
go back to reference Marie I, Dominique S, Janvresse A, Levesque H, Menard JF. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med. 2012;106(4):581–7.CrossRefPubMed Marie I, Dominique S, Janvresse A, Levesque H, Menard JF. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med. 2012;106(4):581–7.CrossRefPubMed
59.
go back to reference Keir GJ, Maher TM, Ming D, Abdullah R, Lauretis A de, Wickremasinghe M, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19(3):353–9.CrossRefPubMed Keir GJ, Maher TM, Ming D, Abdullah R, Lauretis A de, Wickremasinghe M, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19(3):353–9.CrossRefPubMed
60.
go back to reference Andersson H, Sem M, Lund MB, Aalokken TM, Gunther A, Walle-Hansen R, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford). 2015;54(8):1420–8.CrossRef Andersson H, Sem M, Lund MB, Aalokken TM, Gunther A, Walle-Hansen R, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford). 2015;54(8):1420–8.CrossRef
61.
go back to reference Sharp C, McCabe M, Dodds N, Edey A, Mayers L, Adamali H, et al. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatology (Oxford). 2016;55(7):1318–24.CrossRef Sharp C, McCabe M, Dodds N, Edey A, Mayers L, Adamali H, et al. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatology (Oxford). 2016;55(7):1318–24.CrossRef
62.
go back to reference Chartrand S, Swigris JJ, Peykova L, Fischer A. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2016;32(4):296–304.PubMed Chartrand S, Swigris JJ, Peykova L, Fischer A. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2016;32(4):296–304.PubMed
63.
go back to reference Sari A, Guven D, Armagan B, Erden A, Kalyoncu U, Karadag O, et al. Rituximab experience in patients with long-standing systemic sclerosis-associated interstitial lung disease: a series of 14 patients. J Clin Rheumatol. 2017;23(8):411–5.CrossRefPubMed Sari A, Guven D, Armagan B, Erden A, Kalyoncu U, Karadag O, et al. Rituximab experience in patients with long-standing systemic sclerosis-associated interstitial lung disease: a series of 14 patients. J Clin Rheumatol. 2017;23(8):411–5.CrossRefPubMed
64.
go back to reference Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years’ experience at a single centre. Rheumatology (Oxford). 2017;56(8):1348–57.CrossRef Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years’ experience at a single centre. Rheumatology (Oxford). 2017;56(8):1348–57.CrossRef
65.
go back to reference Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017;18(1):275. https://doi.org/10.1186/s13063-017-2016-2.CrossRef Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017;18(1):275. https://​doi.​org/​10.​1186/​s13063-017-2016-2.CrossRef
Metagegevens
Titel
Behandeling met biologicals bij systeemziekten en ILD
Auteurs
Dr. Marcel Veltkamp
Drs. Milou C. Schimmelpennink
Publicatiedatum
20-03-2018
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Bijblijven / Uitgave 2/2018
Print ISSN: 0168-9428
Elektronisch ISSN: 1876-4916
DOI
https://doi.org/10.1007/s12414-018-0298-2

Andere artikelen Uitgave 2/2018

Bijblijven 2/2018 Naar de uitgave